Skip to Main Content

A Randomized, Parallel-arm, Phase 2 Clinical Trial of the Combination of Glasdegib (PF-04449913) with Two Standard Decitabine Regimens for Older Patients with Poor-Risk Acute Myeloid Leukemia who are Unfit for or Refuse Intensive Chemotherapy

Conditions

Myeloid and Monocytic Leukemia

Phase II

What is the purpose of this trial?

This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either refuse or are ineligible for intensive therapy.

  • Trial with
    Yale Cancer Center
  • Start Date
    10/06/2019
  • End Date
    12/20/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/18/2019
  • Study HIC
    #2000024738